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Flow cytometric methods commonly used to identify reticulocytes
are of limited usefulness in malarious areas, since RNA staining also
detects plasmodia. An important antigen expressed on
reticulocytes is Duffy antigen receptor for chemokines (DARC, also
known as Fy), the receptor for Plasmodium vivax. An early marker
for reticulocytes is CD71 (transferrin receptor). We have been
interested in CD71 as an alternative marker for reticulocytes in the
context of Fy expression. Flow cytometry was used to determine
the expression of Fy on CD71-positive and -negative reticulocytes
and to correlate serology and genotype. A reduction of 13 percent
was seen in Fy6 expression between CD71-positive reticulocytes
and RNA-positive reticulocytes. CD71 disappears early during
reticulocyte maturation, while Fy6 expression is relatively
preserved. CD71 is an alternative to staining for RNA for
reticulocyte assays relating to Fy6 expression.
Immunohematology 2005;21:15–20.
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With the discovery of the Duffy system, it became
apparent there are two codominant alleles, Fya and
Fyb, that correspond to the two codominant antigens,
Fya and Fyb, respectively.1 However, in many of those of
African descent, including African Americans, neither
antigen is expressed.2 These individuals have been
described as Duffy negative, with the allelic
designation Fy. Subsequently, it has been shown that
this phenotype, which expresses neither Duffy antigen
receptor for chemokines (DARC) mRNA nor protein, is
caused by a nucleotide polymorphism in the GATA-1
binding site of the promoter regions: a single T to C
substitution at nucleotide -46.3 This change in the
promoter region prevents downstream transcription of
the open reading frame (ORF). It is noteworthy,
though, that DARC is expressed on other tissues,
including brain, kidney, and endothelial cells of post-
capillary venules,even in those with the Duffy-negative
phenotype.4 That is, in the Duffy-negative phenotype,
Fy is silent only in the erythroid lineage.
Other Duffy-related epitopes have been discovered
serologically. DARC follows the general structure of
chemokine receptors, having seven transmembrane-
spanning helices. Anti-Fy3 antibody attaches to the
third extracellular loop in a pocket where chemokines
themselves attach to their receptor.5 It was initially
described as a human antibody but now a mouse
monoclonal is available. Anti-Fy4 and anti-Fy5 are rare
and clinically unimportant human antibodies.1 Anti-
Fy6 is a mouse monoclonal antibody that attaches to
the first extracellular domain of DARC, in an area
thought to correspond to the binding site of
Plasmodium vivax merozoites.6,7
The functional role of Fy on RBCs is not known,but
it has been speculated that it acts as a “sink” for
chemokines, removing them from the circulation.8 The
absence of Fy antigens or proteins on the RBCs of
Africans,resulting in the serologic Fy(a–b–) phenotype,
however, has no discernible ill effect. Similarly, no ill
effect has been seen in other rare examples, of
Caucasians with mutations leading to lack of functional
Fy expression on all tissues.9 Whether consequent
elevated chemokine levels in these individuals might
have a protective effect against malaria or other
infectious diseases is a question for future
investigation. There is certainly evidence that
chemokine levels may vary according to Fy phenotype,
as do outcomes in some disease models.10,11
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P. vivax is known to preferentially invade
reticulocytes. It is proposed that this is due to the
presence of a second receptor on the surface of
reticulocytes12 that is perhaps not present on more
mature RBCs. However, no second receptor has yet
been identified. Recently we developed a flow
cytometric assay to measure the relative amount of Fy6
on reticulocytes and demonstrated an increased
expression of Fy6 on these cells compared to mature
RBCs.13 Expression of the Fy6 epitope was higher (49
± 19%) on reticulocytes than on mature RBCs,
regardless of donor genotype (p < 0.0001).13 We have
speculated that this may be due to relative differences
in size, membrane structure, RNA activity, or some
combination of these.
The transferrin receptor (CD71) is a transmembrane
glycoprotein involved in iron metabolism, specifically
the cellular uptake of transferrin, during erythrocyte
ontogeny. Its persistent presence, after release from the
bone marrow, defines an early population of reticulo-
cytes.14 Therefore, the relative expression of Fy6 on
CD71-positive and -negative reticulocytes may define the
extent and timing of loss of Fy6 from maturing
reticulocytes, all of which stain with thiazole orange
(TO), the stain commonly used to identify reticulocytes
in flow cytometric assays. Because TO also stains the
RNA of any plasmodia present, we wished to evaluate
the use of CD71 as an alternative marker for reticulo-
cytes in this assay. Used in this way, it may be an
acceptable alternative labeling method for samples from
areas where malaria is endemic. The main objective of
this study was to develop such a method and specifically
look at the profile of DARC expression on reticulocytes
less mature than those that do not express CD71, to see
if that pattern was consistent with DARC’s role as a
“sink” for chemokines in the circulation, as theorized, or
with its having an important role in RBC ontogeny in the
bone marrow.
Materials and Methods 
Samples
Samples were obtained from bag segments
prepared from units of whole blood donated at the
American Red Cross Blood Services, Northern Ohio
Region. Racial designation was by donor self-
identification.
Methods
RBC phenotyping for Fya and Fyb was performed
using standard blood bank reagents and methods. DNA
was isolated from samples using the QIA blood kit
(Qiagen, Santa Clarita, CA). Genotyping of the FY
promoter and open reading frame polymorphisms was
performed by PCR-RFLP strategies.13
Flow cytometry studies were done using an anti-
Fy6 antibody (NYBC-BG6), kindly provided by John
Barnwell, Centers for Disease Control and Prevention,
Atlanta, Georgia. This antibody binds to the extra-
cellular portion of the Fy glycoprotein involved in
interaction of the reticulocyte surface with the P.vivax
merozoite ligand.7 This antibody was conjugated
directly to a phycoerythrin (PE) label (ProZyme, San
Leandro, CA) according to the manufacturer’s
instructions. Prior experiments were done to
determine the optimum concentration and incubation
time for labeling erythrocytes. A 5 µL aliquot of blood
was washed three times in 50 µL of 2% BSA/PBS with
0.1% sodium azide. The RBCs were then incubated
with 50 µL of a 1:50 dilution of PE-labeled anti-Fy6 
for 15 minutes at 37°C. Cells were again washed twice
with 2% BSA/PBS with 0.1% sodium azide. A second
mouse antibody against human CD71 (Caltag,
Burlingame, CA) labeled with TC (Tricolor) was added
at a dilution of 1:50 and incubated for 15 minutes. The
RBCs were then washed twice in PBS and resuspended
in TO solution (Becton Dickinson, San Jose, CA) for 30
minutes to stain reticulocytes, according to the
manufacturer’s specifications. Flow cytometry
readings were performed using a Coulter Elite
instrument (Coulter Corp., Miami, FL) equipped with a
488-nm air-cooled argon ion laser at 15 mW. TO, PE,
and TC fluorescence was collected with band pass
filters at 525 nm, 575 nm, and 675 nm, respectively.
Compensation was applied at the level of the hardware
after the appropriate initial experiments, i.e., after
controls were run, negative fluorescent signals were
adjusted until orthogonal. Forward scatter, side scatter,
and fluorescence data were analyzed. A count of 5000
TO-positive cells was taken per sample. This was
approximately 1 to 2 percent of the total number of
cells assayed for each individual. Experiments were
standardized using Quantum Simply Cellular Beads
(Flow Cytometry Standards Corp., San Juan, PR) and
Immunobrite beads (Coulter) according to the
manufacturers’ instructions. Analysis was undertaken
using Win MD 2.8 software (Dr. Joe Trotter, BD
Biosciences, accessed at http://facs.scripps.edu/
software.html), using the quadrant tool to gate upon
the populations of interest. Care was taken in the use
of the quadrant tool to reduce background.
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Correlation coefficients for mean fluorescence
were calculated using Pearson’s bivariate analysis, and
statistical analysis was undertaken with the SPSS 10
software package (SPSS Inc., Chicago, IL).
Results
Genotyping was performed on samples from 33
donors. Samples were classified according to promoter
and ORF polymorphisms. Twenty were homozygous
for the wild-type promoter, six were heterozygous, and
seven were homozygous for the promoter
polymorphism. In the group homozygous for the wild-
type promoter, ten were FY*A/FY*A for the ORF, one
was FY*A/FY*B, and nine were FY*B/FY*B. All but
three of these donors identified themselves as white;
the others self-identified as African American. Among
the six persons who were heterozygous for the
promoter polymorphism, two were FY*A/FY*B for the
ORF and four were FY*B/FY*B. Five of these donors
were self-identified as African American and one as
white. As expected, all seven who were homozygous
for the promoter polymorphism were FY*B/FY*B.
These individuals were all self-identified as African
American. Serologic findings were consistent with
genotyping in these donors.
Characteristic flow cytometric dot plots obtained
for RBCs from individuals with each of the three
different promoter genotypes are shown in Figure 1.
The X axis demonstrates the amount of PE fluo-
rescence (Fy6) and the Y axis the reticulocyte markers
as measured by TO fluorescence (RNA) or TC
fluorescence (CD71). Graphs were prepared with Win
2.8 MD software. Donor A is homozygous for the wild-
type promoter, donor B is heterozygous, and donor C is
homozygous for the GATA-1 promoter polymorphism
(i.e., having no Fy expression on RBCs). In the first
column, TO expression is a marker for reticulocytes.
In the second column,TC is used as the marker for the
presence of CD71. PE fluorescence represents Fy6
expression. A vertical line has been drawn to delineate
the main population of cells. Values from the upper 
left quadrant of each panel therefore represent
reticulocytes, and values from the lower left quadrant
represent mature RBCs.
The flow cytometry and genotyping results for all
33 subjects are summarized in Table 1 (mature RBCs)
and Table 2 (reticulocytes). They show a high degree
of correlation between the two methods of measuring
Fy expression. Table 3 shows the percentage of each
population labeled with TC (CD71-positive) and TO
(RNA-positive). The mean reduction in Fy expression
between early, CD71-positive reticulocytes and the
population of reticulocytes as a whole was only 13
percent. Therefore, there is a strong degree of
correlation between the results of the two flow
cytometric assays for Fy6 expression on reticulocytes.
Discussion
The key finding from this study was that DARC
expression is relatively preserved during reticulocyte
maturation. Comparing immature reticulocytes and
the total reticulocyte population (at least four-fifths of
which are CD71 negative), Fy6 expression is relatively
stable in the life of the reticulocyte, falling by a mean of
13 percent as CD71 is lost. This is in keeping with
previously published data showing the antigen appears
late in the bone marrow during ontogeny of RBCs.15
Fig. 1. Representative flow cytometric curves for RBCs from donors
with and without Fy expression on RBCs. The panels in row (A)
represent a serologically Duffy-positive individual who is
homozygous for the wild-type promoter. The panels in row (B)
represent a donor heterozygous for that polymorphism; those in
row (C) show a serologically negative individual who is
homozygous for the promoter polymorphism. Panels in the first
column show PE fluorescence, which represents the Fy6 epitope
versus TO. Panels in the second column show PE versus TC,
which represents CD71, or the transferrin receptor, for the same
individuals. The mean fluorescent intensity (MFI) of the left
upper quadrant has been used as representative of double-
labeled cells to reduce background. These MFI values for the top
panel are 32.7 and 30.7 (TO/PE and TC/PE respectively), for the
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Assuming a constant rate of reticulocyte release into
the circulation and subsequent maturation to RBCs,
these results also demonstrate the relatively early
disappearance of CD71 from reticulocytes. The loss of
CD71 is consistent with previous studies. Although the
mean percentage of cells expressing CD71 (15% ± 5%)
in the present study is lower than has been reported in
some previous studies using similar methods on
homozygous wild-type promoter populations,14 it is
consistent with the findings of others. For instance, in
a flow cytometry–based study that did not examine Fy
expression, Dertinger et al.16 found it was the youngest
10 to 20 percent of reticulocytes that label with anti-
CD71. Thus very large numbers of cells must be
Table 1. Level of Fy6 expression on mature RBCs according to Fy promoter and ORF genotype as measured by MFI
Mature RBCs Mature RBCs
Promoter ORF RNA (TO) negative CD71 (TC) negative Correlation coefficient
genotype genotype Number MFI ± SD MFI ± SD (Pearson’s bivariate)
Homozygous FY*A/FY*A 10 14.55 ± 4.95 14.66 ± 4.99
wild-type promoter FY*A/FY*B 1 6.2 6.2
FY*B/FY*B 9 10.38 ± 2.57 10.44 ± 2.58
All 20 12.26 ± 4.56 12.34 ± 4.60 1.00
Heterozygous FY*A/FY*A 0 – –
wild-type promoter FY*A/FY*B 4 5.63 ± 0.98 5.73 ± 0.98
FY*B/FY*B 2 3.75 ± 0.35 3.75 ± 0.35
All 6 5.12 ± 1.20 5.07 ± 1.28 1.00
Total Fy positive 26 10.5 ± 5.08 10.66 ± 5.11 1.00
Homozygous FY*B/FY*B 7 1.57 ± 0.10 1.57 ± 0.10 1.00
promoter polymorphism
(Fy negative)
Table 2. Level of Fy6 expression on reticulocytes according to Fy promoter and ORF genotype as measured by MFI
Reticulocytes Reticulocytes Correlation coefficient
Promoter ORF RNA (TO) positive CD71 (TC) positive TO+ versus TC+ 
genotype genotype Number MFI ± SD MFI ± SD populations
Homozygous FY*A/FY*A 10 24.25 ± 8.30 24.37 ± 11.82
wild-type promoter FY*A/FY*B 1 9.9 15.2
FY*B/FY*B 9 19.42 ± 3.33 24.25 ± 8.30
All 20 21.36 ± 7.10 23.91 ± 9.13 0.771
Heterozygous FY*A/FY*A 0 – –
wild-type promoter FY*A/FY*B 4 10.63 ± 1.04 13.53 ± 2.35
FY*B/FY*B 2 7.9 ± 0.00 12.35 ± 0.49
All 6 9.72 ± 1.62 13.13 ± 1.93 0.469
Total Fy positive 26 18.67 ± 7.99 21.42 ± 9.25 0.831
Homozygous FY*B/FY*B 7 2.04 ± 0.26 4.2 ± 1.2
promoter polymorphism
(Fy negative)
Table 3. Percentage of reticulocytes (TO+) staining positive for CD71 (TC+) by genotype
Percentage of
Promoter ORF African reticulocytes TO+ also
genotype genotype Number White American CD71 (TC) + Serology
Homozygous FY*A/FY*A 10 10 0 16 ± 7 10 Fy(a+b–)
wild-type promoter FY*A/FY*B 1 1 0 19 1 Fy(a+b+)
FY*B/FY*B 9 6 3 13 ± 3 9 Fy(a–b+)
All 20 17 3 15 ± 5
Heterozygous FY*A/FY*A 0 0 0 –
wild-type promoter FY*A/FY*B 4 1 3 15 ± 6 4 Fy(a+b–)
FY*B/FY*B 2 0 2 23 ± 10 2 Fy(a–b+)
All 6 1 5 18 ± 8
Total Fy positive 26 16 ± 7
Homozygous FY*B/FY*B 7 7 18 ± 8 7 Fy(a–b–)
promoter polymorphism
(Fy negative)
Note: No significant differences are noted.
Race
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analyzed to obtain a sufficiently large sample of CD71-
bearing cells for statistical analysis of their antigen
expression.
The persistence of relatively constant quantities of
Fy on the RBC surface supports the prevailing theory
that DARC’s major role is as a “sink” for circulating
chemokines. On the other hand, a large difference
between the two sets of reticulocytes may have
implied a role for Fy6 in RBC development.
Our findings that, first, there is a gene dosage effect
associated with the promoter polymorphism and,
second, the Fyb polymorphism in the ORF is
independently associated with lower Fy expression,
confirmed results previously reported.13 An incidental
finding is the apparent higher expression of DARC on
the cells of persons with the Fy(a+b–) phenotype as
compared to the Fy(a–b+) phenotype, a finding
consistent with previous studies using the same
antibody.13 Whether this is due to a true difference in
Fy expression or a difference in antibody affinity is
unclear.
This study demonstrates the ease of using three-
color flow cytometry to examine RBC antigen
expression during maturation. Similar techniques may
be used to define subpopulations of maturing
reticulocytes in individual patients and to distinguish
between mixtures of cell populations, for example,
identifying donor or patient reticulocytes in the
posttransfusion setting.17 This technique may be useful
when the putative reticulocyte-specific receptor for P.
vivax malaria is identified and to measure the decline
of other RBC surface markers in the circulation. Clearly
this technique is unlikely to be of use in African
populations who have no Fy expression on RBCs.
However, the global burden of malaria includes 70 to
80 million cases annually, about 10 to 20 percent of
which occur in Africa. The rest occur predominantly in
South America, the Southwest Pacific, and Asia,18 so
there are large populations potentially suitable for
study of this technique. In addition, it seems unlikely
that in vitro, and perhaps in vivo, RBC exposure to
malaria alters DARC antigen expression on RBCs.19
Consequently, we would not likely see artifactual
changes postvenipuncture secondary to malaria.
However, it cannot be ruled out, since these studies
were performed on healthy blood donors, in whom
other factors, such as anemia, malaria, or
hemoglobinopathies, might not be significantly
different. As DARC is only expressed on erythrocytes,
there should be no confounding effect due to the
relatively small number of WBCs in the circulation that
express CD71 and contain RNA. In addition, of course,
the absolute number of WBCs is much smaller than the
number of RBCs.
Finally, this study evaluated the utility of CD71 as a
reticulocyte marker alternative to RNA labeled by TO.
Comparable Fy6 expression on reticulocytes is
obtained using staining for either CD71 or RNA, which
allows comparison of data from different populations,
including those exposed to malaria. The role of
transferrin receptor in malaria pathogenesis, if any, is
unknown. Studies of soluble levels of transferrin
receptor in malaria have led to contradictory results,
with levels said to be both lower and higher than
expected,20,21 possibly dependent upon disease
severity. The techniques reported here may be a useful
adjunct to exploring reticulocyte biology, in the future,
with special relevance to malaria.
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